MRVI(Maravai LifeSciences Holdings, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $799.24M | $883.00M | $288.94M | $259.19M | $185.74M |
| 毛利润 | $658.68M | $714.04M | $140.20M | $108.31M | $33.99M |
| 营业利润 | $554.64M | $574.22M | −$31.65M | −$235.62M | −$215.27M |
| 净利润 | $182.04M | $220.21M | −$119.03M | −$144.85M | −$130.77M |
| 经营现金流 | $368.57M | $535.98M | $126.22M | $7.46M | −$57.57M |
| 自由现金流 | $353.72M | $518.89M | $60.67M | −$22.19M | −$70.72M |
| 摊薄每股收益 | — | — | $-0.90 | $-1.05 | $-0.90 |